Hikma Pharmaceuticals Plc Holding(s) in Company (9510Y)
December 11 2017 - 4:33AM
UK Regulatory
TIDMHIK
RNS Number : 9510Y
Hikma Pharmaceuticals Plc
11 December 2017
TR-1: Standard form for notification of major holdings
LONDON, 11 December 2017 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (DIFX: HIK)
(LEI: 549300BNS685UXH4JI75), the fast-growing multinational
pharmaceuticals group,
announces as follows:
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant
issuer and to the FCA in Microsoft Word format if possible)(i)
----------------------------------------------------------------------------------------------------
1a. Identity of the issuer Hikma Pharmaceuticals plc
or the underlying issuer
of existing shares to which
voting rights are attached(ii)
:
------------------------------------------------- -------------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer
(please mark with an "X" if appropriate)
----------------------------------------------------------------------------------------------------
Non-UK issuer
------------------------------------------------------------------------------------- -------------
2. Reason for the notification (please mark the appropriate
box or boxes with an "X")
----------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights X
------------------------------------------------------------------------------------- -------------
An acquisition or disposal of financial instruments
------------------------------------------------------------------------------------- -------------
An event changing the breakdown of voting rights
------------------------------------------------------------------------------------- -------------
Other (please specify)(iii) :
------------------------------------------------------------------------------------- -------------
3. Details of person subject to the notification obligation(iv)
Name The Capital Group Companies,
Inc. ("CGC")
City and country of registered Los Angeles, CA 90071, USA
office (if applicable)
4. Full name of shareholder(s) (if different from 3.)(v)
----------------------------------------------------------------------------------------------------
Name
------------------------------------------------- -------------------------------------------------
City and country of registered
office (if applicable)
------------------------------------------------- -------------------------------------------------
5. Date on which the threshold 7 December 2017
was crossed or reached(vi)
:
------------------------------------------------- -------------------------------------------------
6. Date on which issuer notified 11 December 2017
(DD/MM/YYYY):
------------------------------------------------- -------------------------------------------------
7. Total positions of person(s) subject to the notification
obligation
----------------------------------------------------------------------------------------------------
% of voting % of voting Total of Total number
rights attached rights through both in % of voting
to shares financial (8.A + 8.B) rights of
(total of instruments issuer(vii)
8. A) (total of
8.B 1 + 8.B
2)
---------------------- ------------------------- ---------------- ---------------- -------------
Resulting
situation
on the date
on which
threshold
was crossed
or reached 10.7829% 0.0000% 10.7829% 240,662,305
---------------------- ------------------------- ---------------- ---------------- -------------
Position
of previous
notification
(if
applicable) 9.8262% 0.0000% 9.8262%
---------------------- ------------------------- ---------------- ---------------- -------------
8. Notified details of the resulting situation on the
date on which the threshold was crossed or reached(viii)
--------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
--------------------------------------------------------------------------------------------------------------
Class/type Number of voting rights(ix) % of voting rights
of
shares
ISIN code
(if possible)
-----------------------
Direct Indirect Direct Indirect
(Art 9 of (Art 10 of (Art 9 of (Art 10 of
Directive Directive Directive Directive
2004/109/EC) 2004/109/EC) 2004/109/EC) 2004/109/EC)
(DTR5.1) (DTR5.2.1) (DTR5.1) (DTR5.2.1)
---------------------- --------------------- -------------- ------------------------------ --------------
Ordinary
Shares
(ISIN: GB00B0LCW083) 25,950,451 10.7829%
----------------------- --------------------- -------------- ------------------------------ --------------
SUBTOTAL
8. A 25,950,451 10.7829%
----------------------- ------------------------------------- ----------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a)
of Directive 2004/109/EC (DTR5.3.1.1 (a))
--------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date(x) Conversion rights that rights
Period(xi) may be acquired
if the instrument
is
exercised/converted.
----------------------- --------------------- -------------- ------------------------------ --------------
SUBTOTAL 8.
B 1
-------------- ------------------------------ --------------
B 2: Financial Instruments with similar economic effect
according to Art. 13(1)(b) of Directive 2004/109/EC
(DTR5.3.1.1 (b))
--------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Physical Number % of voting
financial date(x) Conversion or cash of voting rights
instrument Period settlement(xii) rights
(xi)
---------------------- ---------------------- -------------- ----------------- ----------- --------------
SUBTOTAL
8.B.2
----------------- ----------- --------------
9. Information in relation to the person subject to
the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is
not controlled by any natural person or legal entity
and does not control any other undertaking(s) holding
directly or indirectly an interest in the (underlying)
issuer(xiii)
Full chain of controlled undertakings through which X
the voting rights and/or the
financial instruments are effectively held starting
with the ultimate controlling natural person or
legal entity(xiv) (please add additional rows as
necessary)
----------------------------------------------------------------- ---------------------
Name(xv) % of voting % of voting Total of both
rights if it rights through if it equals
equals or is financial instruments or is higher
higher than if it equals than the notifiable
the notifiable or is higher threshold
threshold than the notifiable
threshold
---------------------- ---------------- ----------------------- ---------------------
The Capital
Group Companies,
Inc.
Holdings by
CG Management
companies are
set out below: 10.7829% 0.0000% 10.7829%
---------------------- ---------------- ----------------------- ---------------------
-- Capital Research
and Management
Company(1) 10.7829% 0.0000% 10.7829%
---------------------- ---------------- ----------------------- ---------------------
(1) Subsidiary of The Capital Group Companies, Inc.
----------------------------------------------------------------------------------------
10. In case of proxy voting, please identify:
----------------------------------------------------------------------------------------
Name of the proxy holder
---------------------------------------- ----------------------------------------------
The number and % of voting
rights held
---------------------------------------- ----------------------------------------------
The date until which the
voting rights will be held
---------------------------------------- ----------------------------------------------
11. Additional information(xvi)
----------------------------------------------------------------------------------------
CGC is the parent company of Capital Research and Management
Company ("CRMC"). CRMC is a U.S.-based investment management
company that manages the American Funds family of mutual
funds. CRMC manages equity assets for various investment
companies through three divisions, Capital Research
Global Investors, Capital International Investors and
Capital World Investors. CRMC in turn is the parent
company of Capital Group International, Inc. ("CGII"),
which in turn is the parent company of five investment
management companies ("CGII management companies"):
Capital Guardian Trust Company, Capital International,
Inc., Capital International Limited, Capital International
Sàrl and Capital International K.K. The CGII management
companies primarily serve as investment managers to
institutional clients.
Neither CGC nor any of its affiliates own shares of
Hikma Pharmaceuticals plc for its own account. Rather,
the shares reported on this Notification are owned by
accounts under the discretionary investment management
of one or more of the investment management companies
described above.
----------------------------------------------------------------------------------------
Place of completion Los Angeles, CA, USA
-------------------- ---------------------
Date of completion 8 December 2017
-------------------- ---------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUAOKRBRAUARA
(END) Dow Jones Newswires
December 11, 2017 04:33 ET (09:33 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024